UBS raised the firm’s price target on Dillard’s (DDS) to $170 from $150 and keeps a Sell rating on the shares. Dillard’s Q1 comp sales decline and elevated inventories reinforce the firm’s view that near-term earnings should remain under pressure, the analyst tells investors in a research note. UBS forecasts a (17%) five-year EPS compound annual growth rate and expects continuous EPS declines.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DDS:
